cyrilzakka/clinical-trials huggingface dataset:
Fetal Ano-genital Distance in 2D Ultrasound.

The purpose of this study is to determine a threshold value of fetal anogenital distance in 2D ultrasound to differentiate male fetuses from female fetuses, starting 18 weeks of gestation and until the due date.

The study also evaluates the feasibility of the measure and its interobserver variability.

The anogenital distance of female newborns is shorter than that of male newborns.

Urogenital disorders, such as hypospadias and micro-penis, are associated with a shorter anogenital distance.

Anogenital distance is a good marker of fetal exposure to androgenic substances.

Prenatal anogenital distance ultrasound measure can help the diagnosis in case of doubt about fetal sexual phenotype or in case of urogenital disorder suspicion (hypospadias or micropenis).

Is the anogenital distance easy to make measure? Can this procedure be reproduced? What are the threshold values to determine fetal sex at each term of pregnancy?

Eligibility Criteria:
Inclusion Criteria:

* pregnant woman
* sonographic fetal follow up in Brest Hospital
* term\>18 weeks of gestation

Exclusion Criteria:

* No datation between 11 weeks of gestation and 13 weeks of gestation and 6 days by crown-rump length measurement
* Minor
* no consent
* ultrasound performed by an operator without ultrasonography graduation
Acid-Associated Heartburn Symptoms and Dose of Esomeprazole

This is a multi-center, double-blind, parallel-group, randomized, proof of concept trial to investigate the relationship between dose of esomeprazole magnesium and acid-associated heartburn symptoms during 4 weeks of treatment. The safety and tolerability of esomeprazole magnesium in doses up to 40 mg BID will also be assessed.


Eligibility Criteria:
Inclusion Criteria:

* Males and non-lactating females, aged 18 to 75 years, inclusive, with the ability to understand English and provide written informed consent
* A history of heartburn for at least 6 months
* A history of prior positive relief of heartburn symptoms from antacids or acid suppressive therapy
* A positive esophageal acid perfusion test
* At least 3 days of 'moderate' severity heartburn over the previous 7 days
* No use of any acid suppression therapy (PPI, H2RA, etc.) within 14 days of randomization

Exclusion Criteria:

* A history of gastric or esophageal surgery
* H. pylori positive
* A history of endoscopy -verified erosive esophagitis within the 16 weeks prior to randomization
* Currently taking higher than the standard approved proton pump inhibitor doses
* Historical evidence of a number of other GI, cardiovascular, pulmonary, liver, kidney, pancreatic, cerebral vascular diseases, organ transplant, or a condition requiring surgery.
Effects of Trunk Training in Patients With Cerebral Palsy

The aim of our study is to compare the effects of NGT-based trunk training, video-based trunk training and video-based trunk training applied with Theratogs in children with hemiparetic type Cerebral Palsy.

The aim of our study is to compare the effects of NGT-based trunk training, video-based trunk training and video-based trunk training applied with Theratogs in children with hemiparetic type Cerebral Palsy. It is planned to include 45 patients with hemiparetic cerebral palsy between the ages of 5-15 and with Gross Motor Function Classification System (GMFCS) level I-III. Patients with cerebral palsy will be divided into 3 groups in a randomized controlled manner. Each group will continue and follow routine physiotherapy and rehabilitation treatments for 8 weeks. Then, structured trunk training will begin. NGT-based trunk training (45 minutes) to the first group, video-based trunk training (45 minutes) to the second group, and Video-based trunk training (45 minutes) will apply with Theratogs to the third group. Treatments will be applied two days a week for 8 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Patients with I-III levels according to Communication Function Classification System
* Patients with I-III levels according to GMFCS
* Patients with Hemiparetic Cerebral Palsy
* Continuing regular physiotherapy and rehabilitation program for six months.

Exclusion Criteria:

* Presence of visual or auditory impairment
* Presence of epilepsy
* Patients who have undergone orthopedic surgery in the last 6 months
* Patients who received Botulinum Toxin-A injection in the last 6 months
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants.

The study will evaluate the safety, tolerability, and the pharmacokinetics (PK) of AZD7503 following multiple subcutaneous doses in healthy Japanese participants.

This is a Phase I, randomised, single-blind, placebo-controlled study. The healthy Japanese participants will receive randomly (3:1) either AZD7503 or placebo subcutaneously.

The study will comprise of:

* A screening period of 28 days.
* Randomization on Day 1.
* A 9-week Treatment Period. Dose 1 will be administered on Day 1. Dose 2 will be administered at the study site on Day 29. Dose 3 will be administered on Day 57.
* A follow-up period of 10 week after last dose of study intervention.
* The total duration of the study will be 23 weeks.

Eligibility Criteria:
Inclusion Criteria:

* For Japanese participants: A Japanese participant is defined as having both parents and 4 Japanese grandparents as confirmed by the interview. This includes second and third generation Japanese whose parents or grandparents are living in a country other than Japan. Participants must have suitable veins for cannulation.
* Females must be of non-childbearing potential.
* Males and females must adhere to the contraception methods.
* Have a Body mass index between 18 and 30 kg/m2 inclusive.

Exclusion Criteria:

* History of any clinically significant disease or disorder in the investigator's opinion.
* History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
* Any clinically important illness, medical/surgical procedure or trauma.
* Any abnormal laboratory values, clinical chemistry, hematology or urinalysis results, vital signs, Electrocardiography.
* Any clinically significant cardiovascular event.
* Participants with known autoimmune disease or on-treatment with immune-modulatory drugs.
* Any positive result at the Screening Visit for serum Hepatitis B surface antigen, hepatitis C antibody and Human Immunodeficiency virus.
* Confirmed COVID-19 infection during screening as per local guidelines.
* History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity.
* Use of any prescribed or nonprescribed medication.
* History of major bleed or high-risk of bleeding diathesis.
* Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of study intervention.
* Participants who have previously received AZD7503 or any investigational drug targeting HSD17B13.
* Vulnerable participants.
Molecular Analysis of Retinoblastoma

Retinoblastoma is a childhood tumor of the retina that affects approximately 1 in 18,000 children. Retinoblastoma is more prevalent in Central America, where most patients present with advanced intraocular and extraocular disease. Therefore, we have formed collaboration with Central American investigators to provide us with frozen retinoblastoma tumors from patients undergoing routine enucleation. The objective of this protocol is to begin to identify the mutations and gene expression changes that occur in retinoblastoma cells following RB1 gene inactivation in order to more effectively target chemotherapy for treating bilateral retinoblastoma.

This is a biology protocol with no treatment regimen associated. Following routine enucleation of the retinoblastoma affected eye, a portion of the tumor will be removed and flash frozen and sent to St. Jude for RNA and DNA analysis. Some tissue will undergo histopathological analysis and tissue microarrays will be isolated.

Eligibility Criteria:
Inclusion Criteria:

* Must have clinical diagnosis of retinoblastoma (to be confirmed histologically after enucleation)
* Legal guardians must willing to sign an informed consent indicating that they are aware of this study and its possible benefits. Legal guardians will be given a copy of the consent form.
* Patient is being seen at this AHOPCA institution:

Exclusion Criteria:

* Ophthalmologist or oncologist is concerned that sampling will interfere with staging.
* Diagnosis other than retinoblastoma.
* Affiliated hospital is unable to provide pathologic evidence of retinoblastoma.
Changes in Vessels After Peripheral Block

In patients with fluid deficit, vasoconstriction occurs in peripheral tissues and blood circulation is kept in the central area. It causes arterial vasodilation and hemodynamic variability by increasing the blood volume of the extremity due to the sympathectomy occurring after the block. When the investigators classify patients according to VCI-CI, it will be questioned whether there is a difference between patients' block quality and hemodynamic variability.

VCI-CI helps us to have an idea about the amount of fluid in patients according to the vena cava Inferior (VCI) diameter and the diameter between the inspiring and expiration. Low arterial diameter and high inspiratory and expiratory variability indicate that the patient's fluid volume may be lower.

In the measurement of VCI diameter, VCI has visualized in the craniocaudal plane thanks to the transverse ultrasound probe. Changes in VCI diameter are observed depending on the negative pressure in the thoracic area during inspiration and expiration. When the difference between this rate of change is greater than 50%, it indicates that the patient has a fluid deficit. The fact that the VCI diameter is also below 1.5 cm indicates that this amount of fluid requirement is more serious. In this study, the investigators will question whether there is a difference between patients' block quality and hemodynamic variability when they classify patients according to VCI-CI.

Eligibility Criteria:
Inclusion criteria:

* Hand and Wrist elective surgery
* Infraclavicular block will be applied
* American Society of Anesthesiologists (ASA) physical condition I-II
* Patients aged 18-65 years

Exclusion Criteria:

* Contraindication for central or peripheral blocks
* Cognitive dysfunction
* History of chronic opioid use
* severe organ dysfunction
* Allergy to any drug used in the study
* Body mass index (BMI) ≥30
* Infection in the area to be treated
* Refusal to participate in the research
Trial of a Patient Education Tool For Leiomyoma

The goal of this study was to assess whether using a multimedia tool would enhance patient education and counseling on uterine leiomyomata.

Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive either standard counseling or multimedia counseling using the drawMD OB/GYN iPad application. Participants completed a pre-counseling questionnaire, received the designated method of counseling, and then completed a post-counseling questionnaire.

Eligibility Criteria:
Inclusion Criteria:

* Non-pregnant
* English speaking
* Women aged 18-60 years
* presence of fibroids confirmed on imaging
* no confirmed or suspicion of malignancy

Exclusion Criteria:

-
Ambulatory Blood Pressure Monitoring for Antihypertensive Treatment Guidance

The purpose of this study is to determine whether in patients with arterial hypertension, treatment guidance using 24-hour blood pressure measurement results in better blood pressure control compared to treatment guidance using office blood pressure measurement.

Blood pressure control in arterial hypertension remains poor, despite the availability of effective drug treatment. Therefore, strategies to increase blood pressure control are urgently needed. 24 hour blood pressure is a better predictor of cardiovascular morbidity and mortality than office blood pressure. Furthermore, the lower variability of measurements over time of 24 hour blood pressure could allow better adjustment of antihypertensive therapy. However, there are only scarce data about antihypertensive treatment adjustment using 24 hour blood pressure instead of office blood pressure.

Aim: To test the hypothesis that a 24 hour blood pressure guided therapy is is more effective in reaching blood pressure control when compared to conventional office blood pressure guided therapy.

Eligibility Criteria:
Inclusion Criteria:

* Uncontrolled hypertension (office BP \>139/89mmHg AND 24h BP \>129/79mmHg)

Exclusion Criteria:

* Severe concomitant illness including heart failure, significant valvular heart disease or malignancy
S-Equol in Alzheimer's Disease (SEAD) Trial

The purpose of this study is to determine if S-equol could benefit persons with Alzheimer's Disease (AD).

Alzheimer's disease (AD) is a progressive brain disorder which causes memory and thinking problems. The exact cause of AD is unknown. Researchers believe mitochondria (the part of your cells that produces energy) might be linked to symptoms of AD. Some studies have shown that patients with Alzheimer's disease have reduced mitochondrial activity or have fewer mitochondria present in neurons. In this study, it is believed that by targeting mitochondria, we might learn more about its influence on AD symptoms.

Mitochondria have a receptor site for estrogen (a hormone) called estrogen receptor β (ERβ). When estrogen attaches to this site, it promotes mitochondrial function. Studies have also suggested ERβ stimulation can cause cells to create new mitochondria. More mitochondria, or increased activity of existing mitochondria, in the cell might have an impact on patients with Alzheimer's disease. One way to measure this increase in function is to look for the presence of an enzyme called COX in your blood. If a drug increases mitochondrial function, there will be an increase in COX concentration in the bloodstream.

By doing this study we hope to learn if S-equol, a compound that acts like estrogen in the body, causes such an increase in mitochondrial activity. We also hope to determine the tolerability of a therapeutic dose of S-equol. It is our goal to advance the understanding of AD, particularly in women.

Eligibility Criteria:
Inclusion Criteria:

* Very mild (CDR 0.5) or mild (CDR 1) AD at time of last KU ADC assessment
* Have a study partner
* Speak English as primary language

Exclusion Criteria:

* No viable study partner
* Report a potentially confounding, serious medical risk such as type 1 diabetes, cancer, or a recent cardiac event (i.e. heart attack, angioplasty, etc.)
* Use any type of estrogen replacement therapy
Assessment of Oxygenation With Oxygen Reserve Index for General Anesthesia

To assess oxygenation with the oxygen reserve index in desflurane anesthesia administration using low and high fresh gas flows for tympanomastoidectomy surgeries.


Eligibility Criteria:
Inclusion Criteria:

* American Society of Anesthesiologists (ASA) risk class I-II,
* Undergoing tympanomastoidectomy

Exclusion Criteria:

* Morbid obesity
* Opioid sensitivity Alcohol or drug addiction
* Chronic obstructive pulmonary disease
* Coronary artery disease,
* Congestive heart failure
* Pronounced anemia
* Have a history of liver or kidney disease
Glycosylation of Exosomes in Prostate and Urothelial Carcinoma

The purpose of this study is to collect a urine sample from patients with prostate and urothelial (bladder) cancer and healthy volunteers who do not have cancer, so that researchers can perform studies on microcellular structures called exosomes that may eventually lead to a new type of urinary biomarker test for prostate and urothelial cancer.

This is a one-time participation, banking study of up to 40 subjects (10 prostate, 10 urothelial, 20 without cancer). Subjects must meet eligibility at the time of informed consent and will donate approx. 200mL of urine sample.

Primary Objective:

To develop alternative and efficient urinary exosome isolation and glycan analysis approaches for especially large glycan structures, including their isomers present at low levels, which will particularly enhance current analytical technology.

To provide further testing of the current microfluidic-based approaches developed to screen glycan samples which this additional specimen will provide to assess whether the current analytical techniques are robust enough to handle this type of sample with sufficient resolution and sensitivity for useful analytical information.

To compare alterations in exosome-derived glycans in adults with prostate and urothelial carcinoma in comparison with the exosome-derived glycans in age-matched healthy adults for assessment of findings to explore if the tools could be applied for future study toward a liquid biopsy test.

Eligibility Criteria:
Inclusion Criteria:

1. Males ≥ 18 years old at the time of informed consent
2. Ability to provide written informed consent and HIPAA authorization
3. Willingness to donate a fasting urine sample for research Patient Cohort

   1. Histologically confirmed prostate or urothelial carcinoma
   2. Localized disease
   3. No neoadjuvant chemotherapy for disease Healthy Volunteer Cohort

   <!-- -->

   1. Healthy volunteers must not have prostate or urothelial carcinoma

Exclusion Criteria:

1. Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical or psychiatric disorder that would interfere with the subject's safety
2. Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent
Oxytocin Administration During Cesarean Section

Cesarean delivery is defined as fetal birth through incisions in the abdominal wall and the uterine wall. This definition does not include removal of the fetus from the abdominal cavity in the case of uterine rupture or in the case of an abdominal pregnancy The guidelines of the Royal College of Obstetricians and Gynaecologists on caesarean section recommend a slow intravenous bolus dose of 5 IU of oxytocin after delivery of the infant. Intravenous oxytocin has a short half life (4-10 minutes); therefore the potential advantage of an oxytocin infusion at caesarean section is in maintaining uterine contractility throughout the surgical procedure and immediate postpartum period, when most primary haemorrhage occurs


Eligibility Criteria:
Inclusion Criteria:

* Primigravida or multigravida
* Term (37 - 42 weeks),
* Singleton pregnancies
* Booked for elective caesarean section.
* Accepting to participate in the study.

Exclusion Criteria:

* • Medical disorders involving the heart, liver, kidney or brain.

  * Diabetes mellitus and hypertension.
  * Blood disorders (e.g. coagulopathies, thrombocytopenia)
  * Patients requiring blood transfusion due to anemia.
  * Risk factors for uterine atony e.g. macrosomia, polyhydramnios and multiple pregnancy.
  * Previous 2 or more cesarean section
  * Placenta previa or placental abruption
  * Previous major obstetric haemorrhage (\>1000 ml) in previous deliveries.
  * Known fibroid or adenomyosis.
  * Women who received anticoagulant therapy.
  * Severe preeclampsis.
  * Uterine anomalies.
The Effect of Virtual Reality Glasses During Endoscopy

Upper gastrointestinal endoscopy is an invasive procedure used to diagnose and treat pathologies in the gastrointestinal mucosa. Since it is an invasive procedure, it can cause anxiety in patients before and pain during the procedure. Virtual reality glasses are an effective method used to reduce the pain and anxiety levels of patients during painful procedures. This study aimed to evaluate the effects of virtual reality glasses on pain, anxiety, and comfort in patients undergoing upper gastrointestinal endoscopy without sedation.

This single-center randomized controlled parallel group study was conducted with 60 patients who underwent upper gastrointestinal endoscopy at the Endoscopy Unit of a training and research hospital in Istanbul. Patients in the virtual reality glasses group (n=30) watched videos of their preferred relaxing nature settings or videos without any violent content during the procedure. Patients in the control group (n=30) received no intervention. Data were collected using the Patient Information Form, Visual Analog Scale (for pain and comfort) and State Anxiety Inventory. Pain, comfort and anxiety levels of patients were assessed five minutes before and five minutes after the procedure.

Eligibility Criteria:
Inclusion Criteria:

* To have an upper gastrointestinal endoscopy for the first time
* To be performed an upper GI endoscopy without sedation
* To be between the ages of 18-75
* To be willing to participate in research

Exclusion Criteria:

* To use analgesic or anesthetic drugs before or during the procedure
* To use antidepressants, anxiolytic and sedative drugs
* To have communication difficulties and mental disability
Prevalence of Eating Disorder Symptomatology Among Outpatients Referred to Health Promotion from Somatic Hospital Departments

The Department of Health Promotion at Aalborg University Hospital gets patients referred from all the hospital's departments. The Department of Health Promotion offers lifestyle courses to aid preventing disease relapses and further comorbidities to patients referred to other ambulatory treatments at the hospital. For most patients this also includes weight loss, but the primary goal is lifestyle change regarding eating and exercise habits to improve overall health state. Since it is known that eating disorders commonly occurs in individuals seeking help for weight loss, and that the prevalence is larger than in the background population, we also suspect that eating disorders would commonly occur among patients referred to the Department of Health Promotion. Therefore, we aim to investigate the prevalence of eating disorders among patients referred to lifestyle courses at the Department of Health Promotion.


Eligibility Criteria:
Inclusion Criteria:

* Patients referred to the Department of Health Promotion at Aalborg University Hospital, Denmark

Exclusion Criteria:

* Under age 18
* Not able to read and understand Danish
* Not able to recieve mail in the danish digital postbox, e-Boks
Mobile Sensing and Support for Depression

The objective of this study is two fold, first to explore the potential of context sensitive intervention delivery to provide in-situ support for people with depressive symptoms, second to explore the detection of daily-life behavior based on smart phone sensor information to identify subjects with a clinically meaningful depression level.

To conduct a very first pilot trial, a monocentric, single-arm clinical study is conducted. The study is approved by the local ethics committee of the Canton of Zurich in Switzerland and the Swiss Agency for Therapeutic Products. It is conducted in full accordance with the Declaration of Helsinki, with all subjects providing their electronic informed consent prior to participation. As the main interest lies in a proof of concept of the proposed MOSS app, emphasis is put on real life conditions. A range of different recruitment channels is used to attract subjects from the general public; they include physical flyers, online posts on relevant online bulletin boards and the Google Play Store.

Eligibility Criteria:
Inclusion Criteria:

* self-declaration of depressive symptoms
* app runs on Android 4.0 and higher
* germen speaking

Exclusion Criteria:

* psychotic symptoms
* bipolar symptoms
* drug or alcohol dependency
* dementia
An RCT of a Smartphone-based TID Programme

The study aims to test the effect a smartphone-based intervention on primary school students and their parents' attitudes towards tobacco industry and their tobacco-related communications.


Eligibility Criteria:
Inclusion Criteria:

* Parents and children should all understand Chinese.
* Parents should have a smartphone and use WhatsApp (a smartphone-based app)

Exclusion Criteria:

* n/a